iLite® ADCC anti-HER2 Assay Ready Cells allow you to measure the ADCC activity of your anti-HER2 antibody in a simple, rapid and sensitive manner.
Therapeutic antibodies are increasingly used to treat different types of cancer, including breast cancer. The activity of a number of therapeutic antibodies is mediated at least in part by antibody dependent cell-mediated cytotoxicity (ADCC), including trastuzumab, an anti-HER2 antibody commonly used for treating HER2 positive breast cancer patients.
This product contains a packaged set of the three individual products, one vial of each:
All three products are genetically engineered human cells to be used for measuring the ADCC activity of anti-HER2 antibodies.
FOR RESEARCH USE ONLY
|Read-out of results||Quantitative,|
|Regulatory status||Research Use Only|
3 vials of iLite® Assay Ready Cells (>250 µL). For contents of the individual vials, please consult the specific product specifications.
Get access to scientific material, posters and more.